Excelsior Medical Future Growth
Future criteria checks 0/6
Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für Excelsior Medical zu prognostizieren.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Healthcare earnings growth | 19.1% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
There's Been No Shortage Of Growth Recently For Excelsior Medical's (TPE:4104) Returns On Capital
Apr 22
A Look At The Intrinsic Value Of Excelsior Medical Co., Ltd. (TPE:4104)
Apr 07What To Know Before Buying Excelsior Medical Co., Ltd. (TPE:4104) For Its Dividend
Feb 25Excelsior Medical (TPE:4104) Could Easily Take On More Debt
Feb 07
Returns On Capital - An Important Metric For Excelsior Medical (TPE:4104)
Jan 22Excelsior Medical (TPE:4104) Has Compensated Shareholders With A Respectable 46% Return On Their Investment
Jan 07Excelsior Medical Co., Ltd. (TPE:4104) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Dec 23Does Excelsior Medical's (TPE:4104) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 08Does Excelsior Medical Co., Ltd. (TPE:4104) Have A Place In Your Dividend Portfolio?
Nov 23In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Excelsior Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2023 | 8,233 | 747 | -36 | 107 | N/A |
| 9/30/2023 | 8,012 | 716 | -53 | 105 | N/A |
| 6/30/2023 | 7,833 | 734 | 13 | 164 | N/A |
| 3/31/2023 | 7,485 | 701 | 183 | 331 | N/A |
| 12/31/2022 | 7,187 | 667 | 465 | 637 | N/A |
| 9/30/2022 | 7,011 | 682 | 775 | 893 | N/A |
| 6/30/2022 | 6,746 | 648 | 573 | 669 | N/A |
| 3/31/2022 | 6,652 | 644 | 683 | 781 | N/A |
| 12/31/2021 | 6,573 | 607 | 776 | 945 | N/A |
| 9/30/2021 | 6,456 | 577 | 916 | 1,087 | N/A |
| 6/30/2021 | 6,566 | 555 | 869 | 1,028 | N/A |
| 3/31/2021 | 6,571 | 564 | 1,125 | 1,261 | N/A |
| 12/31/2020 | 6,675 | 572 | 834 | 869 | N/A |
| 9/30/2020 | 6,709 | 545 | 1,208 | 1,263 | N/A |
| 6/30/2020 | 6,632 | 543 | 1,142 | 1,199 | N/A |
| 3/31/2020 | 6,593 | 523 | 885 | 938 | N/A |
| 12/31/2019 | 6,457 | 515 | 1,142 | 1,194 | N/A |
| 9/30/2019 | 6,387 | 511 | 1,035 | 1,072 | N/A |
| 6/30/2019 | 6,371 | 477 | 804 | 848 | N/A |
| 3/31/2019 | 6,390 | 477 | 192 | 235 | N/A |
| 12/31/2018 | 6,345 | 452 | 156 | 192 | N/A |
| 9/30/2018 | 6,285 | 422 | -428 | -392 | N/A |
| 6/30/2018 | 6,209 | 403 | 12 | 42 | N/A |
| 3/31/2018 | 6,161 | 376 | 385 | 416 | N/A |
| 12/31/2017 | 6,095 | 399 | -524 | -487 | N/A |
| 9/30/2017 | 6,126 | 397 | N/A | -268 | N/A |
| 6/30/2017 | 6,156 | 401 | N/A | 48 | N/A |
| 3/31/2017 | 6,203 | 387 | N/A | -222 | N/A |
| 12/31/2016 | 6,206 | 390 | N/A | 450 | N/A |
| 9/30/2016 | 6,171 | 412 | N/A | 798 | N/A |
| 6/30/2016 | 6,215 | 407 | N/A | 173 | N/A |
| 3/31/2016 | 6,221 | 422 | N/A | 1,006 | N/A |
| 12/31/2015 | 6,203 | 378 | N/A | 740 | N/A |
| 9/30/2015 | 6,123 | 329 | N/A | 610 | N/A |
| 6/30/2015 | 5,995 | 319 | N/A | 535 | N/A |
| 3/31/2015 | 5,898 | 292 | N/A | 368 | N/A |
| 12/31/2014 | 5,807 | 286 | N/A | 737 | N/A |
| 9/30/2014 | 5,864 | 272 | N/A | 566 | N/A |
| 6/30/2014 | 5,846 | 279 | N/A | 883 | N/A |
| 3/31/2014 | 5,813 | 326 | N/A | 71 | N/A |
| 12/31/2013 | 5,741 | 300 | N/A | 357 | N/A |
| 9/30/2013 | 5,620 | 309 | N/A | 73 | N/A |
| 6/30/2013 | 5,609 | 319 | N/A | 357 | N/A |
Analyst Future Growth Forecasts
Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von 4104 über der Sparquote liegt (0.8%).
Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von 4104 schneller wachsen werden als der Markt TW
Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 4104 in den nächsten 3 Jahren signifikant steigen werden.
Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von 4104 schneller wachsen werden als der Markt von TW.
Hohe Wachstumseinnahmen: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Einnahmen von 4104 schneller wachsen werden als 20% pro Jahr.
Earnings per Share Growth Forecasts
Future Return on Equity
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 4104 in 3 Jahren voraussichtlich hoch sein wird